An evaluation of the pharmacokinetic profile of VSLI (vincristine sulfate liposome injection, 0.16 mg/mL) in patients with malignant melanoma and hepatic dysfunction secondary to metastases
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2013
At a glance
- Drugs Vincristine (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- 04 Jan 2012 Primary endpoints identified as reported by ClinicalTrials.gov.
- 06 Dec 2007 Status changed from in progress to completed.
- 30 Oct 2007 Status changed from recruiting to in progress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History